Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results
Director comp.
Acq. announced
Appointed director

Ocuphire Pharma, Inc. (OCUP) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Quarterly results
08/14/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/11/2023 8-K Quarterly results
08/11/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/01/2023 8-K Quarterly results
06/08/2023 4 Ainsworth Sean (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 10,976 shares @ $0
Granted 9,639 options @ $3.83, valued at $36.9k
06/08/2023 4 MANUSO JAMES S J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 10,976 shares @ $0
Granted 9,639 options @ $3.83, valued at $36.9k
06/08/2023 4 Pepose Jay (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 10,976 shares @ $0
Granted 9,639 options @ $3.83, valued at $36.9k
06/08/2023 4 Benton Susan (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 10,976 shares @ $0
Granted 9,639 options @ $3.83, valued at $36.9k
06/08/2023 4 Gallagher Cam (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 10,976 shares @ $0
Granted 9,639 options @ $3.83, valued at $36.9k
06/02/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits  ...
Docs: "Third Amendment to Second Amended and Restated Bylaws of Ocuphire Pharma, Inc"
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/15/2023 8-K Investor presentation, Quarterly results
Docs: "End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy PDUFA date for Nyxol First Indication in Reversal of Pharmacologically-Induced Mydriasis Set for September 28, 2023; Nyxol Development and Commercialization Funded by Viatris",
"Corporate Presentation"
05/01/2023 ARS Form ARS - Annual Report to Security Holders:
05/01/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/26/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/26/2023 3 Form 3 - Initial statement of beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
04/21/2023 8-K Quarterly results
04/05/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/30/2023 8-K Quarterly results
02/14/2023 SC 13G/A Sooch Mina reports a 5.5% stake in Ocuphire Pharma, Inc.
02/14/2023 5 Sooch Mina (President and CEO) has filed a Form 5 on Ocuphire Pharma, Inc.
02/14/2023 5 Ainsworth Sean (Director) has filed a Form 5 on Ocuphire Pharma, Inc.
01/25/2023 8-K Investor presentation
Docs: "Investor Presentation Materials",
"[email protected]"
01/12/2023 4 Sooch Mina (President and CEO) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 134,456 shares @ $0
Granted 201,683 options to buy @ $3.5, valued at $705.9k
01/12/2023 4 MANUSO JAMES S J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 18,544 shares @ $0
01/12/2023 4 Pepose Jay (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 13,013 shares @ $0
Granted 33,291 options to buy @ $3.5, valued at $116.5k
01/12/2023 4 Rodgers Richard J (Director) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 20,822 shares @ $0
01/12/2023 4 Hoffmann Bernhard (SVP of Corp. Dev. & Ops & Sec.) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 46,608 shares @ $0
Granted 69,912 options to buy @ $3.5, valued at $244.7k
01/12/2023 4 Zaremba Rabourn Amy (SVP of Finance) has filed a Form 4 on Ocuphire Pharma, Inc.
Txns: Granted 46,608 shares @ $0
Granted 69,912 options to buy @ $3.5, valued at $244.7k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy